When it comes to pharmacology, the big story these days is the development of the “glucagon-like peptide-1 (GLP-1) mimics,” ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...

Background Both host and microbe metabolism of tryptophan (Trp) is altered in diabetes; however, the molecular mechanisms are ...

A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both ...

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need ...

Importantly, a clinician should also ask about your mental health before prescribing a GLP-1. If you have a history of ...

Obesity is a chronic relapsing condition, and treatment options need to reflect this reality, write Sam West, Dimitrios A Koutoukidis, and Susan A Jebb The use of glucagon-like peptide-1 (GLP-1) ...

HealthDay News — Initiation of incretin receptor agonists (IRAs) is associated with lower continuous positive airway pressure (CPAP) use, hospitalization, and mortality among adults with obesity, type ...

Background: Intestinal dysmotility in type 2 diabetes mellitus (T2DM) may involve impaired cholinergic and incretin-mediated regulation. This study compared cholinergic-induced jejunal contractility ...

Joel F. Habener, a Harvard University academic whose research paved the way for revolutionary weight-loss drugs Ozempic, Mounjaro and others, which analysts forecast will be the biggest blockbusters ...